Up 143% in 5 years, ASX 200 company secures major new data centre contracts

The business is aiming to double data centre profits by FY27.

| More on:
Two IT professionals walk along a wall of mainframes in a data centre discussing various things

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Infratil's data centre business, CDC, has secured about 100MW of new contracted capacity, with 95% of forecast lease revenues now under contract, highlighting strong demand.
  • CDC is on track to double its FY25 earnings by FY27, supported by increasing demand from cloud and AI sectors.
  • With nearly all future revenues secured and a robust pipeline, CDC is set to remain a leader in the Australasian data centre market, positioning Infratil for substantial earnings growth despite a 1% share price decline over the past year.

Yesterday, Infratil Ltd (ASX: IFT) announced that its data centre business, CDC, has secured about 100MW of new contracted capacity. This highlights strong ongoing demand and further solidifies CDC's leadership in the fast-growing Australasian data centre market.

What did Infratil report?

  • CDC secured approximately 100MW of new contracted capacity.
  • About 95% of forecast lease revenues are now under contract following recent deals.
  • CDC remains on track to double FY25 earnings by FY27.
  • Strong customer demand driven by cloud and AI workloads.

What else do investors need to know?

CDC's ability to contract significant new capacity points to ongoing demand from cloud and artificial intelligence customers. The data centre operator's technological advantage and experience are key factors behind its ongoing success.

Recent contract wins mean nearly all of CDC's forecast lease revenues are now locked in, offering investors strong visibility of future earnings. Infratil reaffirmed its confidence in securing the remainder of its upcoming capacity.

What did Infratil management say?

Infratil CEO Jason Boyes said:

This announcement provides high visibility that CDC remains on track to double FY25 earnings by FY27. With other contracts signed since May, approximately 95% of forecast lease revenues are now under contract, and we remain confident in contracting the remaining capacity.

What's next for Infratil?

Infratil expects CDC to remain at the forefront of the Australasian data centre sector, with a strong pipeline for further growth. The company is focused on meeting the increasing demand for large-scale, future-proof campuses, especially those tailored to the rising needs in artificial intelligence.

Management's outlook remains positive as CDC continues to attract new customers and secure long-term contracts, positioning Infratil for robust earnings growth over the next few years.

Infratil share price snapshot

Intrafil shares have fallen around 1% over the past 12 months, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen approximately 8%.

View Original Announcement

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

More on Share Market News

Contented looking man leans back in his chair at his desk and smiles.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

Three small children reach up to hold a toy rocket high above their heads in a green field with a blue sky above them.
Growth Shares

These 4 ASX 200 stocks could jump another 70% to 80% in 2026

These stocks are expected to rocket higher.

Read more »

Two excited woman pointing out a bargain opportunity on a laptop.
Share Gainers

3 ASX 200 stocks jumping higher in this week's falling market

Investors shrugged off the broader market retrace and piled into these three ASX 200 stocks this week.

Read more »

A woman with a sad face looks to be receiving bad news on her phone as she holds it in her hands and looks down at it.
Share Fallers

Why EOS, Lotus Resources, REA, and Web Travel shares are dropping today

These shares are ending the week deep in the red. But why?

Read more »

A businessman looking at his digital tablet or strategy planning in hotel conference lobby. He is happy at achieving financial goals.
Share Gainers

Why Brambles, HMC Capital, ResMed, and Rio Tinto shares are rising today

These shares are avoiding the selloff and are pushing higher on Friday.

Read more »

A woman looks shocked as she drinks a coffee while reading the paper.
Share Fallers

Why is the Web Travel share price crashing 41% on Friday?

ASX investors are pummelling Web Travel shares today. But why?

Read more »

A man looking at his laptop and thinking.
Materials Shares

Rio Tinto shares charge higher after Glencore merger collapses

The parties couldn't come to an agreement.

Read more »

a group of doctors and medical staff in uniform high five in celebration in a hospital setting
Share Market News

Neuren Pharmaceuticals kicks off Phase 3 trial in rare syndrome

Neuren Pharmaceuticals shares are on watch after dosing began in its key Phase 3 trial for Phelan-McDermid syndrome.

Read more »